William Binning
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
William Binning has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Aja E. Hogan-Cann1 shared publication
- Diana Yae Sakae
University of Western Ontario
1 shared publication - Marco Antonio Maximo Prado
Robarts Research Institute, The University of Western Ontario, London, Canada
1 shared publication - Matthew J. E. Maksoud
Graduate Program of Neuroscience, The University of Western Ontario, Canada; Robarts Research Institute, The University of Western Ontario, Canada
1 shared publication - Mohammed A. Al-Onaizi
Robarts Research Institute
1 shared publication - Sara Matovic
University of Western Ontario
1 shared publication
Latest Publications
- Open Access
- 28 January 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Chronic hM3Dq signaling in microglia ameliorates neuroinflammation in male mice
Microglia express muscarinic G protein-coupled receptors (GPCRs) that sense cholinergic activity and are activated by acetylcholine to potentially regulate microglial functions. Knowledge about how distinct types of muscarinic GPCR signaling regulate microglia functionin vitroandin vivois still poor, partly due to the fact that some of these receptors are also present in astrocytes and neurons. We generated mice expressing the hM3Dq Designer Receptor Exclusively Activated by Designer Drugs (DREADD) selectively in microglia to investigate the role of muscarinic M3Gq-linked signaling. We show that activation of hM3Dq using clozapine N-oxide (CNO) elevated intracellular calcium levels and increased phagocytosis of FluoSpheresin vitro. Acute treatment with CNOin vivodid not affect male mouse behavior, however chronic CNO treatment decreased sickness behavior triggered by lipopolysaccharide (LPS) treatment. Interestingly, whereas acute treatment with CNO increased synthesis of cytokine mRNA, chronic treatment attenuated LPS-induced cytokine mRNA changes in the brain, likely explaining the improvement in sickness behavior by chronic hM3Dq activation. No effect of CNO was observed in DREADD-negative mice. These results suggest that chronic activation of M3 muscarinic receptors (the hM3Dq progenitor) in microglia, and potentially other Gq-coupled GPCRs, preconditions microglia to decrease their response to further immunological challenges. Our results indicate that hM3Dq can be a useful tool to modulate neuroinflammation and study microglial immunological memoryin vivo, which may be applicable for manipulations of neuroinflammation in neurodegenerative and psychiatric diseases.Highlights: Microglial function was manipulated by specific activation of hM3Dq signaling. Chronic hM3Dq activation prevented LPS-induced sickness behavior in mice. Microglial hM3Dq signaling modulated expression of pro-inflammatory cytokines.
- 28 January 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Open AccessChronic hM3Dq signaling in microglia ameliorates neuroinflammation in male mice
Microglia express muscarinic G protein-coupled receptors (GPCRs) that sense cholinergic activity and are activated by acetylcholine to potentially regulate microglial functions. Knowledge about how distinct types of muscarinic GPCR signaling regulate microglia functionin vitroandin vivois still poor, partly due to the fact that some of these receptors are also present in astrocytes and neurons. We generated mice expressing the hM3Dq Designer Receptor Exclusively Activated by Designer Drugs (DREADD) selectively in microglia to investigate the role of muscarinic M3Gq-linked signaling. We show that activation of hM3Dq using clozapine N-oxide (CNO) elevated intracellular calcium levels and increased phagocytosis of FluoSpheresin vitro. Acute treatment with CNOin vivodid not affect male mouse behavior, however chronic CNO treatment decreased sickness behavior triggered by lipopolysaccharide (LPS) treatment. Interestingly, whereas acute treatment with CNO increased synthesis of cytokine mRNA, chronic treatment attenuated LPS-induced cytokine mRNA changes in the brain, likely explaining the improvement in sickness behavior by chronic hM3Dq activation. No effect of CNO was observed in DREADD-negative mice. These results suggest that chronic activation of M3 muscarinic receptors (the hM3Dq progenitor) in microglia, and potentially other Gq-coupled GPCRs, preconditions microglia to decrease their response to further immunological challenges. Our results indicate that hM3Dq can be a useful tool to modulate neuroinflammation and study microglial immunological memoryin vivo, which may be applicable for manipulations of neuroinflammation in neurodegenerative and psychiatric diseases.Highlights: Microglial function was manipulated by specific activation of hM3Dq signaling. Chronic hM3Dq activation prevented LPS-induced sickness behavior in mice. Microglial hM3Dq signaling modulated expression of pro-inflammatory cytokines.